Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 14 Sep 2020

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
29 Mar 2020
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.

Eicosapentaenoic acid confers cardioprotection in heart failure

Jairia Dela Cruz
21 Nov 2018

An increased abundance of eicosapentaenoic acid (EPA) is associated with a reduced risk of heart failure (HF), and this protective effect is independent of established risk factors and ejection fraction status, according to a study presented at the American Heart Association (AHA) Scientific Sessions 2018 in Chicago, Illinois, US.

“Given HF is a leading cause of hospitalization and death in the US and globally, and there are currently no effective treatments for HF with preserved ejection fraction (HFpEF), these findings have important clinical implications,” the authors said.

The study included 6,566 adult participants (52 percent female; 38.55 percent Caucasian) from the Multi-Ethnic Study of Atherosclerosis study who had available baseline EPA data. HF occurred in 293 individuals over a median follow-up of 13.0 years, among whom 129 had HF with reduced ejection fraction, 110 had HFpEF and the remaining 54 had unknown ejection fraction status. [AHA 2018, abstract 026]

Compared with HF-free controls, participants who developed HF had significantly lower mean plasma phospholipid EPA levels (0.70 percent vs 0.77 percent; p=0.002).

Cox proportional hazards analysis revealed that increased EPA levels were associated with a lower incidence of HF (hazard ratio [HR] per unit change in percentage of total fatty acids, 0.73; 95 percent CI, 0.60–0.89; p=0.001).

The association persisted despite adjusting for age, sex, race, body mass index, smoking, diabetes mellitus, blood pressure, lipids and lipid-lowering drugs, and albuminuria. Sensitivity analysis showed no dependence on HF type, and controlling for other fatty acids with clustering did not change the risk estimates.

“We have previously demonstrated in a mouse model of pressure overload-induced HF that EPA preserves contractile function and prevents interstitial myocardial fibrosis,” the authors said.

The present data confirm that EPA is similarly protective in humans, they added.

In animals, EPA level of >2.5 percent is required for prevention of HF, between 2.5 percent and 1 percent is marginal, and <1 percent is insufficient. In the present study, most participants (n=4,794) had insufficient EPA levels, fewer (n=1,471) had marginal levels and fewer still (n=301) had sufficient levels.

“[Individuals] with sufficient EPA levels were at 0.40-fold (0.15–0.81) risk compared to [those with] insufficient EPA (p=0.008),” the authors noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 14 Sep 2020

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
29 Mar 2020
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.